The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Lipid-based nanoparticle technologies for liver targeting
Abstract
Liver diseases such as hepatitis, cirrhosis, and hepatocellular carcinoma are global health problems accounting for approximately 800 million cases and over 2 million deaths per year worldwide. Major drawbacks of standard pharmacological therapies are the inability to deliver a sufficient concentration of a therapeutic agent to the diseased liver, and nonspecific drug delivery leading to undesirable systemic side effects. Additionally, depending on the specific liver disease, drug delivery to a subset of liver cells is required. In recent years, lipid nanoparticles have been developed to passively and actively target drugs to the liver. The success of this approach has been highlighted by the FDA-approval of the first liver-targeting lipid nanoparticle, ONPATTRO, in 2018, and many other promising candidate technologies are expected to follow. This review summarizes recent developments of various lipid-based liver-targeting technologies, namely solid-lipid nanoparticles, liposomes, niosomes and micelles, and discusses the challenges and future perspectives in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–249 of 249
In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.
Watanabe, T., Hatakeyama, H., Matsuda, C., Sato, Y., Sudoh, M., Takagi, A., Hirata, Y., Ohtsuki, T., Arai, M., Inoue, K., et al. (2014) · Scientific Reports · doi:10.1038/srep04750 · Cited by 54
Akita, H., Noguchi, Y., Hatakeyama, H., Sato, Y., Tange, K., Nakai, Y., & Harashima, H. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00203 · Cited by 54
Adrian, J. E., Poelstra, K., Scherphof, G. L., Meijer, D. K. F., van Loenen-Weemaes, A. M., Reker‐Smit, C., Morselt, H. W. M., Zwiers, P. J., & Kamps, J. A. A. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117945 · Cited by 53
Cervantes, A. M. R., Alsina, M., Tabernero, J. M., Infante, J. R., LoRusso, P. M., Shapiro, G. I., Paz-Ares, L. G., Falzone, R., Hill, J., Cehelsky, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3025 · Cited by 53
Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes
Tang, W.-L., Tang, W.-H., Chen, W. C., Diako, C., Ross, C. F., & Li, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00077 · Cited by 51
Self-citationA phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).
Demeure, M. J., Armaghany, T., Ejadi, S., Ramanathan, R. K., Elfiky, A. A., Strosberg, J., Smith, D. C., Whitsett, T. G., Liang, W. S., Sekar, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2547 · Cited by 49
Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma
Liang, J., Zhang, X., Miao, Y., Li, J., & Gan, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s128525 · Cited by 49
Koning, G. A., Morselt, H. W. M., Gorter, A., et al. (2003) · Pharmaceutical Research · doi:10.1023/a:1025009300562 · Cited by 48
Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance
Aubé, C., Bazeries, P., Lebigot, J., Cartier, V., & Boursier, J. (2017) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2017.03.003 · Cited by 48
Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
Setten, R. L., Lightfoot, H. L., Habib, N., & Rossi, J. J. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180611093428 · Cited by 48
Ukawa, M., Akita, H., Hayashi, Y., Ishiba, R., Tange, K., Arai, M., Kubo, K., Higuchi, Y., Shimizu, K., Konishi, S., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300629 · Cited by 45
Hatakeyama, H., Murata, M., Sato, Y., Takahashi, M. M., Minakawa, N., Matsuda, A., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.023 · Cited by 44
Nanoparticles for human liver-specific drug and gene delivery systems:in vitroandin vivoadvances
Kasuya, T., & Kuroda, S. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802622096 · Cited by 44
Tsend-Ayush, A., Zhu, X., Ding, Y. J., Yao, J., Yin, L., Zhou, J., & Yao, J. (2017) · Nanotechnology · doi:10.1088/1361-6528/aa66ba · Cited by 42
de Ilarduya, C. T., & Düzgüneş, N. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.837447 · Cited by 41
Wang, C., Kemp‐Harper, B. K., Kočan, M., Ang, S. Y., Hewitson, T. D., & Samuel, C. S. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00091 · Cited by 41
Gregoriadis, G. C. (1992) · Research in Immunology · doi:10.1016/s0923-2494(92)80161-d · Cited by 40
Toriyabe, N., Hayashi, Y., Hyodo, M., & Harashima, H. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1084 · Cited by 39
Liu, D., Hu, H., Zhang, J., Zhao, X., Tang, X., & Chen, D. (2011) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.59.63 · Cited by 39
MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?
Roosbroeck, K. V., & Călin, G. A. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.015 · Cited by 39
Liu, X., Han, M., Xu, J., Geng, S., Zhang, Y. X., Ye, X., Gou, J., Yin, T., He, H., & Tang, X. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.02.010 · Cited by 38
Adrian, J. E., Kamps, J. A. A. M., Poelstra, K., Scherphof, G. L., Meijer, D. K. F., & Kaneda, Y. (2007) · Journal of drug targeting · doi:10.1080/10611860601141481 · Cited by 37
Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics
Zhang, J., Garrison, J. C., Poluektova, L. Y., Bronich, T. K., & Osna, N. A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.014 · Cited by 34
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Parasitic Infections
Edwards, G., & Krishna, S. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1113-9 · Cited by 34
Rafique, A., Etzerodt, A., Graversen, J. H., Moestrup, S. K., Dagnæs‐Hansen, F., & Møller, H. J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s192113 · Cited by 34
Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes
Detampel, P., Witzigmann, D., Krähenbühl, S., & Huwyler, J. (2013) · Journal of drug targeting · doi:10.3109/1061186x.2013.860982 · Cited by 33
Higashi, N., Sato, M., Kojima, N., Irie, T., Kawamura, K., Mabuchi, A., & Senoo, H. (2005) · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · doi:10.1002/ar.a.20230 · Cited by 32
A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine
Pireddu, R., Pibiri, M., Valenti, D., Sinico, C., Fadda, A. M., Simbula, G., & Lai, F. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.048 · Cited by 32
Akhter, A., Hayashi, Y., Sakurai, Y., Ohga, N., Hida, K., & Harashima, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.048 · Cited by 31
Tang, S., & Li, Y. (2019) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2019.16936 · Cited by 31
Lai, C., Li, C., Luo, X., Liu, M., Liu, X., Hu, L., Kang, L., Qiu, Q., Deng, Y., & Song, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00042 · Cited by 30
Li, Q., Yan, Z., Li, F., Lu, W., Wang, J., & Guo, C. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/26/265101 · Cited by 28
Azmin, M. N., Florence, A. J., Handjani-Vila, R.-M., et al. (1986) · Journal of Microencapsulation · doi:10.3109/02652048609031563 · Cited by 28
Tang, W.-L., Chen, W. C., Roy, A., Undzys, E., & Li, S. (2016) · Pharmaceutical Research · doi:10.1007/s11095-015-1854-4 · Cited by 27
Self-citationPhospholipid‐Free Small Unilamellar Vesicles for Drug Targeting to Cells in the Liver
Zhang, W., Böttger, R., Qin, Z., Kulkarni, J. A., Vogler, J., Cullis, P. R., & Li, S. (2019) · Small · doi:10.1002/smll.201901782 · Cited by 27
Self-citationLiver metastases from colorectal cancer: drug delivery with liposome-encapsulated doxorubicin.
Cay, O., Kruskal, J. B., Nasser, I. A., Thomas, P., & Clouse, M. E. (1997) · Radiology · doi:10.1148/radiology.205.1.9314969 · Cited by 25
Christensen, E., Henriksen, J. R., Jørgensen, J. T., Amitay, Y., Schmeeda, H., Gabizón, A., Kjær, A., Andresen, T. L., & Hansen, A. E. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s182579 · Cited by 24
Advances in Lipid-Based Platforms for RNAi Therapeutics
Falsini, S., Ciani, L., Ristori, S., Fortunato, A., & Arcangeli, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400791q · Cited by 23
Role of polymer–drug conjugates in organ-specific delivery systems
Paramjot, Khan, N. M., Kapahi, H., Kumar, S., Bhardwaj, T., Arora, S., & Mishra, N. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1016436 · Cited by 23
APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA
Niemietz, C., Nadzemova, O., Zibert, A., & Schmidt, H. H.-J. (2020) · Amyloid · doi:10.1080/13506129.2019.1681392 · Cited by 22
Hsu, C., Chen, C., Aljuffali, I. A., Dai, Y.-S., & Fang, J. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0319 · Cited by 20
Zhang, Q., Zhang, X., Chen, T., Wang, X., Fu, Y. S., Jin, Y., Sun, X., Gong, T., & Zhang, Z. (2015) · Nanoscale · doi:10.1039/c4nr04730c · Cited by 19
Development and clinical applications of siRNA-encapsulated lipid nanoparticles in cancer
Lin, P. J. C., Tam, Y. K., & Cullis, P. R. (2014) · Clinical Lipidology · doi:10.2217/clp.14.27 · Cited by 18
Patel, G., Kher, G., & Misra, A. R. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.610800 · Cited by 17
Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System
Hayashi, Y., Hatakeyama, H., Kajimoto, K., Hyodo, M., Akita, H., & Harashima, H. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00184 · Cited by 14
Kara, A., Rouillard, C., Mathault, J., Boisvert, M., Tessier, F., Landari, H., Melki, I., Laprise-Pelletier, M., Boisselier, É., Fortin, M., et al. (2016) · Italian National Conference on Sensors · doi:10.3390/s16060778 · Cited by 14
Delivery of cisplatin by folic acid-targeted liposomal nanoparticles into liver cancer cell line
Foroud, N., Ardjmand, M., Heydarinasab, A., & Akbarzadeh, A. (2017) · International Journal of Polymeric Materials · doi:10.1080/00914037.2017.1393676 · Cited by 8
Lee, A. C. H., Thi, E. P., Cuconati, A., Ardzinski, A., Holland, R., Huang, H., Kondratowicz, A. S., Kowalski, R., Palmer, L., Pasetka, C., et al. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30929-6 · Cited by 8
In vivo transfer and expression of the liposome encapsulated rat insulin gene.
Nicolau, C. S., Pape, A. L., Soriano, P. M., Fargette, F., Jp, M., & Mf, J. (1982) · PubMed · Cited by 5
Cited by
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Self-citationIn vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Peng, M., Shao, M., Dong, H., Han, X., Hao, M., Yang, Q., Lyu, Q., Tang, D., Shen, Z., Wang, K., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04473-2 · Cited by 22
Metadata
- Authors
- Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 154-155
- Pages
- 79-101
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3036456250
- Cited by
- 264
- References
- 249
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.